The global mRNA vaccine is anticipated to grow at a 16% CAGR during the forecast period (2022-2028). The mRNA vaccine is a nucleic acid-based vaccine containing the messenger RNA’s that allows patients' cells to produce protein as a part of the treatment option. The rising prevalence of chronic diseases such as diabetes, tuberculosis, and cardiovascular diseases (CVD), is one of the major drivers in boosting the growth of the global mRNA vaccines market. For instance, according to World Health Organization (wHO), in 2020, an estimated 10 million people fell ill with tuberculosis (TB) globally, out of which 5.6 million are men, 3.3 million are women and 1.1 million are children. According to International Diabetes Federation (IDF), in 2021, around 537 million adults (20-79 years) were living with diabetes. Further, as per the same source, the total number of people living with diabetes is anticipated to rise to 643 million by 2030. Similarly, according to World Health Organization (WHO), an estimated 17.9 million people died from CVD in 2019, representing 32% of all global mortalities. Thus, the rising prevalence of chronic diseases is anticipated to propel the growth of the global mRNA vaccine market during the forecast period.

Impact of COVID-19 on Global mRNA Vaccine Market 

The COVID-19 pandemic has positively impacted the global mRNA vaccine market owing to the rise in the number of prominent players conducting clinical trials for vaccine development. For instance, in July 2020, Moderna has announced its phase 3 study of its mRNA vaccine against COVID-19 and further started dosing participants in July 2020. Thus, an increase in the prevalence of COVID-19  cases, is one of the major factors that positively impacted the growth of the global mRNA vaccine market. 

Segmental Outlook 

The global mRNA vaccine is segmented based on type and application. Based on the type, the market is further sub-segmented into a bioengineered vaccine, gene therapy, cell therapy, monoclonal antibody-based treatment, and others. Based on the application, the market is further sub-segmented into infectious disease and cancer. Among these, the gene therapy segment is anticipated to hold a considerable share in the market over the forecast period owing to the rising prevalence of target diseases.?

Global mRNA Vaccine Market by Application,  2021 (%)

The Cancer Segment is Anticipated to Hold a Prominent Share in the Global mRNA Vaccine.

The rise in the prevalence of cancer is anticipated to drive the market during the forecast period. For instance, as per the World Health Organization (WHO), cancer is a leading cause of death worldwide accounting for nearly 10 million mortalities in 2020. The most common cancers are breast, lung, colon, and prostate cancers. Cancer-causing infections such as hepatitis and human papillomavirus are responsible for 30% of cancer cases in low and lower-middle-income countries. Moreover in 2021, according to the national center for health statistics, 18,96,180 new cases cancer cases and 6,08,570 cancer mortalities were recorded in the U.S.  Thus, a rise in the prevalence of cancer is anticipated to drive the cancer segment, further boosting the growth of global mRNA vaccine market.

Regional Outlook 

The global mRNA vaccine is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America).  The market can be analyzed for a particular region or country level as per the requirement. Among these, the Asia-Pacific region is anticipated to hold a considerable share in the market owing to the increase in the prevalence of non-communicable diseases in the region. Moreover, investments in the vaccine development process are anticipated to hamper the market in the region.

Global mRNA Vaccine Market, by Region 2022-2028

North America Region is Anticipated to Hold a Prominent Share in Global mRNA Vaccine Market 

The North American region is anticipated to hold a prominent share in the global mRNA vaccine market owing to an increase in the number of COVID-19 cases in the U.S. and the presence of prominent players operating in the U.S. For instance, in  May 2020, according to the data published by the Centers for Disease Control and Prevention (CDC), the COVID-19 pandemic resulted in 5,817,385 reported cases and 362,705 mortalities globally, including 17,61,503 aggregated reported cases and 10,37,00 deaths in the US. Moreover, the existence of prominent players in the US such as Moderna, Pfizer, Johnson &Johnson Services Inc, and others have contributed a considerable share in the region. For instance, in August 2021, Pfizer-BioNTech has received approval from Food and Drug Administration (FDA) to market the vaccines under the brand names. The Pfizer-BiotNtech Covid -19 vaccine for individuals ages 16 and older were marketed as CORMINATY. Thus, owing to the increase in COVID-19 cases and the presence of prominent market players in the region, the global mRNA vaccine market is anticipated to grow at a significant rate during the forecast period. 

Market Players Outlook

The major companies serving the global mRNA Vaccine market are Arcturus Therapeutics Inc, BioNTech SE, CureVac AG, GlaxoSmithKline.Plc, ethris GmbH, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For Instance, in  July 2021 Eurofins Agroscineces Services (EAS) announced that Pete Coody, Ph.D., and Martin Cole, Ph.D., is working in partnership with EAS Hercules laboratory in North America to support the continued growth and development of the company’s Environment Disaster Assessment and Exercise System.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global mRNA vaccine market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.